Authors
Hongru Tao, Ningyun Liu, Ziang Hu, Yixuan Xu, Heng Xu, Yuanyuan Zhang, Cheng Luo
Published in
Free radical biology & medicine. Oct 18, 2026. Epub Oct 18, 2026.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited targeted options, and its progression is strongly driven by metabolic reprogramming and redox homeostasis. Here, we found that peroxiredoxin-1 (PRDX1) promotes TNBC progression by directly interacting with glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP). Mechanistically, PRDX1 depletion reduced the formation of active G6PD dimers without affecting its expression, thereby impairing PPP metabolism and ultimately suppressing TNBC growth. Furthermore, we identified the natural product Oridonin as a small-molecule disruptor that blocked the PRDX1-G6PD interaction. Pharmacological intervention with Oridonin impaired G6PD dimerization, disrupted intracellular redox homeostasis and suppressed TNBC tumor growth in vivo. Taken together, our study unveils the critical role of the PRDX1-G6PD protein complex in PPP-dependent metabolic reprogramming and redox homeostasis in TNBC, and identifies this axis as a targetable vulnerability against TNBC.
PMID:
42893758
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 27
- Comments 0